Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15399080 | 1.00 | POLB (0.43) | POLBHTTMITFMAPTPREP | |
| SCHEMBL20666655 | 1.00 | POLB (0.43) | POLBHTTMITFMAPTPREP | |
| SCHEMBL9640980 | 1.00 | POLB (0.43) | POLBHTTMITFMAPTPREP | |
| SCHEMBL819017 | 1.00 | POLB (0.43) | POLBHTTMITFMAPTPREP | |
| SCHEMBL114481 | 1.00 | POLB (0.43) | POLBHTTMITFMAPTPREP | |
| SCHEMBL28747 | 1.00 | POLB (0.43) | POLBHTTMITFMAPTPREP | |
| SCHEMBL820890 | 0.91 | POLB (0.43) | POLBPREPPDK1PDK2PDK3 | |
| SCHEMBL7488827 | 0.91 | POLB (0.43) | POLBPREPPDK1PDK2PDK3 | |
| SCHEMBL819549 | 0.91 | POLB (0.43) | POLBPREPPDK1PDK2PDK3 | |
| SCHEMBL7131978 | 0.91 | POLB (0.43) | POLBPREPPDK1PDK2PDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698020-B | Macrocyclic RIP 2-kinase inhibitors | 昂科迪塞恩精密医药公司(OPM) | 2025-02-25 | — | — | CN | disclosed |
| WO-2025037940-A1 | PYRAZOLE-1-CARBOXAMIDES AS RIP1 KINASE INHIBITORS | BISICHEM CO., LTD. (KR) | 2025-02-20 | — | — | WO | disclosed |
| EP-4440700-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| EP-0272456-B1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
| EP-0243686-B1 | BETA-LACTAM COMPOUNDS, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-5093328-A | Carbapenicillin antibiotics | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-03-03 | — | — | US | disclosed |
| US-4822787-A | 3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid compounds and antimicrobial activity thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| EP-0272456-A1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0243686-A2 | Beta-lactam compounds, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084467-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | POLB 1226/4885HTT 3181/4885MITF 4603/4885 |
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | POLB 3282/4885HTT 2144/4885MITF 2259/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | POLB 1226/4885HTT 3181/4885MITF 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.